Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Community Health (CYH)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wuxi Biologics (Cayman) (WXIBF) and Community Health (CYH) with bullish sentiments.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Wuxi Biologics (Cayman) (WXIBF)
Morgan Stanley analyst Laurence Tam maintained a Buy rating on Wuxi Biologics (Cayman) on July 9 and set a price target of HK$50.00. The company’s shares closed last Wednesday at $4.60.
Tam has an average return of
According to TipRanks.com, Tam is ranked #8290 out of 12381 analysts.
Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of $6.27, representing a 32.0% upside. In a report issued on July 5, TipRanks – PerPlexity also upgraded the stock to Buy with a HK$44.00 price target.
See the top stocks recommended by analysts >>
Community Health (CYH)
In a report issued on July 9, Ben Hendrix from RBC Capital maintained a Buy rating on Community Health, with a price target of $5.00. The company’s shares closed last Friday at $3.57.
According to TipRanks.com, Hendrix is a 5-star analyst with an average return of
Currently, the analyst consensus on Community Health is a Hold with an average price target of $3.50.
Read More on WXIBF:
Disclaimer & DisclosureReport an Issue
- WuXi Biologics Wins Full Shareholder Backing at 2026 AGM
- Wuxi Biologics Grants Time-Based Restricted Shares to 21 Employees
- WuXi Biologics Schedules 2026 Business Update Calls for Investors
- WuXi Biologics Launches US$400 Million Share Buyback Plan
- WuXi Biologics Sets 2026 AGM to Vote on Board, Auditors and New Share Mandate
